NCT00408005

Clinical Trial Information

Trial Number: NCT00408005 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Acute Lymphoblastic Leukemia
Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma

Trial Title:

Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma

Study ID:

AALL0434

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00408005-D4	NCT00408005-D4: There is 1 dataset associated with the PMID 32813610. This dataset, NCT00408005-D4, provides the information for generating all tables, figures, and numbers in the manuscript. It includes all patients who enrolled on COG study AALL0434. There is one row for each patient enrolled. The data cutoff is 06/30/2018.
NCT00408005-D2	There are two data submissions (NCT00408005-D1 and -D2) for PMID 30138085. This dataset, NCT00408005-D2, provides specific incidence of adverse events in interest. This dataset is necessary to construct Table A4 (IM Toxicities by Treatment Regimen (Grades 3 and 4) in the manuscript.
NCT00408005-D1	There are two data submissions (NCT00408005-D1 and -D2) for PMID 30138085. This dataset, NCT00408005-D1, has one row for each patient enrolled. The dataset provides the information of consort diagram of patient enrollment, baseline characteristics, induction response, and primary outcome for the patients on AALL0434 as reported in the manuscript.

Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security

U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

NIH…Turning Discovery Into Health^®